Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

All NewsJuly 22, 2025

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp’ tech to strengthen its respiratory vaccine pipeline.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent